All In Biotech

Drug Trial Radar · NCT01939366

Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

Efficacy, Safety and Tolerability of Multiple Doses of Oral Cebranopadol in Subjects With Moderate to Severe Chronic Pain Due to Diabetic Peripheral Neuropathy.

Last checked: Nov 20, 2026Latest source record: Jul 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 699 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

699

Actual

Start

Sep 27, 2013

Primary completion

Jan 2015

Study completion Jan 28, 2015

Sponsor

Lead sponsor
Tris Pharma, Inc.Industry
Sponsor type
Industry
First posted
Sep 11, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to evaluate if cebranopadol is safe and can decrease pain in patients when compared to placebo (a tablet that does not contain active product) and when compared to a marketed product containing pregabalin (Lyrica®). Furthermore, this trial will be undertaken to find out if the patient's general health and well-being improves under trial treatment. The concentrations of cebranopadol in the blood will be investigated to get a better understanding of how it is absorbed from the gut, distributed and broken down in the body, and eliminated from the body.

Conditions

  • Chronic Pain
  • Diabetic Neuropathies
  • Diabetes Mellitus

Interventions

  • Cebranopadol 100 µgDrug

    Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.

  • Cebranopadol 300 µgDrug

    Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.

  • Cebranopadol 600 µgDrug

    Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.

  • PregabalinDrug

    Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.

  • Matching PlaceboDrug

    Placebo will be matched to pregabalin and cebranopadol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Average Pain Intensity.Time frame: Baseline; to End of Week 6 of the Maintenance Phase

Locations

82 sites in 8 countries. Site status is shown where the registry gives one.

  • US002

    Mesa, Arizona

  • US001

    Garden Grove, California

  • US019

    Laguna Hills, California

  • US014

    National City, California

  • US007

    Orange, California

  • US011

    Hialeah, Florida

  • US012

    Miami, Florida

  • US009

    Orlando, Florida

  • US004

    Blackfoot, Idaho

  • US006

    Elgin, Illinois

  • US016

    West Long Branch, New Jersey

  • US008

    Brooklyn, New York

  • US005

    Brooklyn, New York

  • US021

    New York, New York

  • US003

    West Jordan, Utah

  • AT007

    Graz, Austria

  • AT005

    Salzburg, Austria

  • AT004

    Senftenberg, Austria

  • AT002

    Vienna, Austria

  • AT003

    Vienna, Austria

  • AT001

    Vienna, Austria

  • AT006

    Vienna, Austria

  • DK005

    Aalborg, Denmark

  • DK003

    Aarhus, Denmark

  • DK002

    Copenhagen, Denmark

  • DK001

    Odense, Denmark

  • FR008

    Corbeil-Essonnes, France

  • FR001

    Lille, France

  • FR007

    Limoges, France

  • FR005

    Montauban, France

  • FR002

    Nantes, France

  • FR004

    Orléans, France

  • FR006

    Paris, France

  • DE018

    Aschaffenburg, Germany

  • DE003

    Bad Oeynhausen, Germany

  • DE005

    Berlin, Germany

  • DE023

    Berlin, Germany

  • DE031

    Berlin, Germany

  • DE004

    Berlin, Germany

  • DE025

    Berlin, Germany

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.